2026-02-24
Joint Health and Cartilage Support: What the Evidence Shows
Cartilage has limited self-repair capacity, but several interventions modestly slow degradation and reduce symptoms. Here is what the clinical evidence supports for joint health in aging.
2026-02-19
Fisetin and Senolytic Research: Human Data, Protocol Context, and Limitations
Fisetin has a strong preclinical senolytic rationale, while human evidence remains early-stage with limited placebo-controlled outcome data.
2026-02-19
Glucosamine for Joints: Cartilage Evidence, Cardiovascular Signal, and Sulfate vs Hydrochloride
Glucosamine sulfate has modest RCT evidence for slowing cartilage loss and reducing joint pain in knee osteoarthritis. An unexpected but consistent epidemiological signal links glucosamine use with lower cardiovascular mortality — the mechanism may involve AMPK activation.
2026-02-18
Dasatinib and Quercetin for Senolytic Therapy: Mayo Clinic Phase 2 Trial Findings
A Mayo Clinic Phase 2 trial tested dasatinib plus quercetin in 60 older women with low bone density, finding improved bone formation markers. Dasatinib is an FDA-approved cancer drug requiring physician supervision.
2026-02-16
Collagen Peptides: Joint Pain, Skin Aging, Bone Density, and Bioavailability Evidence
Hydrolyzed collagen peptides are absorbed as dipeptides and tripeptides that accumulate in cartilage, skin, and bone tissue. RCTs show meaningful joint pain reduction in osteoarthritis and sports-related joint discomfort. Skin hydration and elasticity benefits are well-replicated. Evidence for bone density is emerging.